Navigation Links
CV Therapeutics Reports 2008 Second Quarter Financial Results
Date:7/31/2008

or the prior quarter of $28.0 million. The decrease in cash utilization in the quarter ended June 30, 2008 compared to the prior quarter was due primarily to the timing of certain compensation and payroll related tax payments paid out in the prior quarter and higher cash receipts in the current quarter associated with higher quarter-over-quarter revenue.

Company management will webcast a conference call on July 31, 2008 at 5:00 p.m. EDT, 2:00 p.m. PDT, on the Company's website. To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6241, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Thursday, August 7, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 56235490.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and Lexiscan(TM) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to underg
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... and NEW ORLEANS , May 22, ... field of regenerative medicine, presented new data generated in ... Group (a leading health economics consultancy) demonstrating the significant ... (DFU) and venous leg ulcers (VLU) place upon the ... this research, which reveal annual costs of up to ...
(Date:5/22/2013)... Express Diagnostics Int’l, Inc. (EDI) , ... pleased to announce a sponsorship agreement with Erebus Motorsport ... distributor of DrugCheck® onsite testing devices, manufactured by EDI. ... Austin 400 May 17-19 in Austin, Texas. , Royal ... each car of the Erebus Motorsport team displaying the ...
(Date:5/22/2013)... -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, ... in vivo production of therapeutic proteins, announced today ... Moderna in early July as its first Chief Information ... in the design and implementation of information systems underlying ... clinical operations and commercial preparedness. John has also been ...
(Date:5/21/2013)... WA (PRWEB) May 21, 2013 Through ... trainings, and funds for lab equipment, 25 organizations will ... and importance of optics and photonics in daily life ... . , The organizations, located in 10 countries, are ... to be awarded by SPIE, the international society ...
Breaking Biology Technology:Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 2Learning About Light: Education Outreach Projects Funded in 10 Countries Through First Round of SPIE Grants 3
... Partners B.V., a leading,GMP biopharmaceutical manufacturer, announced today ... ActoGeniX, drug substance AG011 for use in a,Phase ... ActoGeniX is focused on the development and commercialization ... can,be orally administered. The Company,s lead product AG011 ...
... JERSEY CITY, New Jersey, May 14, Rosetta Genomics (Nasdaq: ... financial results on May 21, 2008, before the,U.S. markets ... a,simultaneous webcast to discuss these results at 4:30 p.m. ... conference call, U.S. and Canadian participants may,dial +1-866-966-5335; international ...
... May 14 Access Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) ... Rodman & Renshaw 5th Annual Global Healthcare Conference to ... Hotel in Monte Carlo, Monaco.,Jeffrey B. Davis, CEO of ... at 3:10 pm local time, 9:10 am Eastern time ...
Cached Biology Technology:SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials 2SynCo Bio Partners Completes Manufacture and Release of ActoGeniX' Lead Product for Phase II Clinical Trials 3Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results 2Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference 2
(Date:5/21/2013)... A new analysis shows that the nation,s land ... enough algae to produce up to 25 billion gallons ... one-twelfth of the country,s yearly needs. , The findings ... that would be needed to grow significant amounts of ... were published in the May 7 issue of ...
(Date:5/21/2013)... Researchers at USC have found that a class of ... mice. , The drugs, known as "TSPO ligands," ... "We looked at the effects of TSPO ligand in ... stage, and in aged mice when pathology was quite ... Davis School of Gerontology. "TSPO ligand reduced measures of ...
(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... French . MONTREAL, March 1, 2011 ... rare genetic disease, researchers have discovered how three genes contribute ... understanding of many disorders such as foetal and childhood growth ... result of the Human Genome Project, we know the basic ...
... Cambridge, MASS- When your brain encounters sensory stimuli, such as ... a honking car, that input gets shuttled to the appropriate ... olfactory cortex, while sounds are processed in the auditory cortex. ... follows a predetermined, genetic blueprint. However, evidence is mounting that ...
... Canuel of the Virginia Institute of Marine Science ... Canada, and Mexico who have been awarded a ... As a Leopold Fellow, Canuel will participate in ... Capitol Hilldesigned to promote effective communication of science ...
Cached Biology News:Researchers looking at a rare disease make breakthrough that could benefit everyone 2Researchers looking at a rare disease make breakthrough that could benefit everyone 3MIT-- parts of brain can switch functions 2MIT-- parts of brain can switch functions 3MIT-- parts of brain can switch functions 4VIMS professor selected as Leopold Fellow 2VIMS professor selected as Leopold Fellow 3
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
... Supply, 1. 1000 V, 400 mA, ... and constant power modes.Single-unit increments in ... reproducibility.Stores and recalls three protocols.Outstanding choice ... Multiphor II or GenePhor systems. ...
Mouse TrkC Affinity Purified Polyclonal Ab...
Immunogen: Full length M32 fusion protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: